Research


New directions for the FDA in the 21st century

Biostatistics

View abstract

Moore’s Law Vs. Murphy’s Law in the Financial System: Who’s Winning?

Journal of Investment Management 15 (2017), 17–38.

View abstract

Letter to Senators Wyden and Grassley: comment on their Sovaldi report

View abstract

Buying Cures vs. Renting Health: Financing Healthcare via Consumer Loans

with Vahid Montazerhodjat and David Weinstock, Science Translational Medicine 8(2016), 327ps6

View abstract

The Wisdom of Twitter Crowds: Predicting Stock Market Reactions to FOMC Meetings via Twitter Feeds

with Pablo D. Azar, Journal of Portfolio Management 42(2016), 123–134.

View abstract

TRC Networks and Systemic Risk

with Roger Stein, Journal of Alternative Investment 18(2016), 52–67.

View abstract

Health, Wealth, and the 21st Century Cures Act

with Tomas Philipson and Andrew von Eschenbach, JAMA Oncology 2(2016), 17–18.

View abstract

Price, Value, and the Cost of Cancer Drugs

with Tito Fojo  , Lancet Oncology 17(2016), 3–5.

View abstract

Business Models to Cure Rare Disease: A Case Study of Solid Biosciences

with Esther Kim, Journal of Investment Management 14(2016), 87–101.

View abstract

Q Group Panel Discussion: Looking to the Future

with Martin Leibowitz, Robert C. Merton, Stephen A. Ross, and Jeremy Siegel, Financial Analysts Journal

View abstract

Follow me on © 2018 Andrew W. Lo, MIT Sloan School of Management. All rights reserved.
Design by: Opus Design